You cannot register for this webinar

Theriva Biologics is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company's transformed pipeline incorporates lead clinical-stage drug candidate, VCN-01, a systemically-administered oncolytic adenovirus engineered to break down the stroma barrier that protects tumors from cancer therapies and hides them from the patient's immune system. Theriva has established preclinical proof-of-concept with their unique Albumin Shield™ platform, which is designed to protect systemically administered OVs from inactivation by the patient's immune system. These unique and differentiated mechanisms are intended to improve the anti-tumor effect of the OV and co-administered chemotherapy and immuno-oncology products. Importantly, degrading the stroma can also expose tumor antigens, turning 'cold' tumors 'hot' and enable a sustained anti-tumor response by the patient's immune system.